Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.AIDS (London, England) · 2016
   Pooled it
2. HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial.PloS one · 2017
   Trial
3. Incidence and Clinical, Virological, and Resistance Characteristics of HIV Infections Among pre-Exposure Prophylaxis Users in Spain (SCOPE Study): A Multicentre Prospective and Retrospective Cohort Study.The Lancet regional health. Europe · 2026
   Article
4. Preparedness of Primary Health Care Clinic (PHCC) Providers for the Provision of Oral Pre-exposure Prophylaxis (PrEP) to Adolescent Girls and Young Women (AGYW): Experiences from KwaZulu-Natal, South Africa.AIDS and behavior · 2026
   Article
5. Another Tool for the Sexual Health Toolkit: US Health Care Provider Knowledge and Attitudes About Doxycycline Postexposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infections Among Men Who Have Sex With Men.Sexually transmitted diseases · 2025
   Article
6. Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials-The Ring Study and DREAM.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
   Observational
7. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
   Observational
8. Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care.Journal of general internal medicine · 2017
   Review
9. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.Journal of acquired immune deficiency syndromes (1999) · 2016
   Article
10. How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact.PloS one · 2016
    Article
11. Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment.Open forum infectious diseases · 2015
    Review
12. The current status of the use of oral medication to prevent HIV transmission.Current opinion in HIV and AIDS · 2015
    Review

Corrections and comments

• Comment on
  Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.2015

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as